Clinical Trial Update: A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III trial evaluating E0167 to prevent recurrence of hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• E0167

Snippet

Sponsor: Eisai Limited | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: TERMINATED